Return To Growth In Biosimilars A Priority For Biogen

Full-Year Biosimilars Revenue Expected To Be Down Versus 2021

 
• By Chloe Kent
Growth man drawing graph pen
Biogen has listed biosimilars growth as one of its priorities. • Source: Christian Horz / Alamy Stock Photo

More from Earnings

More from Business